PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives

查看全文 作　　者：Yumeng [1]Wang;Guiling [1,2]Li

机构地区：[1]Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Fudan University, Shanghai 200011, China;[2]Department of Integration of Western and Traditional Medicine, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China

出　　处：《Frontiers of Medicine》索引2019年第13卷第4期,共13页

基　　金：This work was supported by the National Natural Science Foundation of China (No. 81373867). 摘　　要：Cervical cancer (CC) is the fourth most commonly diagnosed female malignancy and a leading cause of cancer-related mortality worldwide, especially in developing countries. Despite the use of advanced screening and preventive vaccines, more than half of all CC cases are diagnosed at advanced stages, when therapeutic options are extremely limited and side effects are severe. Given these circumstances, new and effective treatments are needed. In recent years, exciting progress has been made in immunotherapies, including the rapid development of immune checkpoint inhibitors. Checkpoint blockades targeting the PD-1/PD-L1 axis have achieved effective clinical responses with acceptable toxicity by suppressing tumor progression and improving survival in several tumor types. In this review, we summarize recent advances in our understanding of the PD-1/PD-L1 signaling pathway, including the expression patterns of PD-1/PD-L1 and potential PD-l/PD-Ll-related therapeutic strategies for CC. 关键词：PD-1 PD-L1 immune CHECKPOINT BLOCKADE antibody IMMUNOTHERAPY CERVICAL cancer

相关文献

参考文献（102）
引证文献（19）
耦合文献（0）

参考文献(102)

引证文献(19)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives

参考文献(102)

引证文献(19)

用户提示